{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:24:23Z","timestamp":1783981463150,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Although cutaneous squamous cell carcinoma (cSCC) is common, lymph node metastases are relatively rare and are usually treated with lymph node dissection (LND). The aim of this study was to describe the clinical course and prognosis after LND for cSCC at all anatomical locations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective search at three centres was performed to identify patients with lymph node metastases of cSCC who were treated with LND. Prognostic factors were identified by uni- and multivariable analysis.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 268 patients were identified with a median age of 74. All lymph node metastases were treated with LND, and 65% of the patients received adjuvant radiotherapy. After LND, 35% developed recurrent disease both locoregionally and distantly. Patients with more than one positive lymph node had an increased risk for recurrent disease.<\/jats:p>\n                <jats:p>165 (62%) patients died during follow-up of whom 77 (29%) due to cSCC. The 5-year OS- and DSS rate were 36% and 52%, respectively. Disease-specific survival was significantly worse in immunosuppressed patients, patients with primary tumors &gt;2cm and patients with more than one positive lymph node.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study shows that LND for patients with lymph node metastases of cSCC leads to a 5-year DSS of 52%. After LND, approximately one-third of the patients develop recurrent disease (locoregional and\/or distant), which underscores the need for better systemic treatment options for locally advanced cSCC. The size of the primary tumor, more than one positive lymph node, and immunosuppression are independent predictors for risk of recurrence and disease-specific survival after LND for cSCC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-023-13306-9","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T18:09:24Z","timestamp":1680113364000},"page":"5017-5026","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma"],"prefix":"10.1245","volume":"30","author":[{"given":"Eva A.","family":"Huis in \u2019t Veld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Boere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte L.","family":"Zuur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel W.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C. J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B. A. G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne B.","family":"Crijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antien","family":"Mooyaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Wakkee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniel","family":"Sewnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk C.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"Grunhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winan J.","family":"van Houdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"issue":"2","key":"13306_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/CCO.0000000000000359","volume":"29","author":"S Ribero","year":"2017","unstructured":"Ribero S, Stucci LS, Daniels GA, Borradori L. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence? Curr Opin Oncol. 2017;29(2):129\u201335.","journal-title":"Curr Opin Oncol."},{"issue":"10","key":"13306_CR2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","volume":"151","author":"HW Rogers","year":"2015","unstructured":"Rogers HW, Weinstock MA, Feldman SR. Coldiron BM 2012 incidence estimate of nonmelanoma skin cancer (Keratinocyte Carcinomas) in the US population. JAMA Dermatol. 2015;151(10):1081\u20136.","journal-title":"JAMA Dermatol."},{"issue":"5","key":"13306_CR3","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","volume":"166","author":"A Lomas","year":"2012","unstructured":"Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069\u201380.","journal-title":"Br J Dermatol."},{"key":"13306_CR4","doi-asserted-by":"publisher","first-page":"f6153","DOI":"10.1136\/bmj.f6153","volume":"347","author":"L Lansbury","year":"2013","unstructured":"Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ. 2013;347:f6153.","journal-title":"BMJ."},{"issue":"7","key":"13306_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/jso.23155","volume":"106","author":"ND Brougham","year":"2012","unstructured":"Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol. 2012;106(7):811\u20135.","journal-title":"J Surg Oncol."},{"issue":"3","key":"13306_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamadermatol.2018.4219","volume":"155","author":"ZC Venables","year":"2019","unstructured":"Venables ZC, Autier P, Nijsten T, Wong KF, Langan SM, Rous B, et al. Nationwide incidence of metastatic cutaneous squamous cell carcinoma in England. JAMA Dermatol. 2019;155(3):298\u2013306.","journal-title":"JAMA Dermatol."},{"issue":"27","key":"13306_CR7","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.2217\/fon-2019-0158","volume":"15","author":"ET Petersen","year":"2019","unstructured":"Petersen ET, Ahmed SR, Chen L, Silapunt S, Migden MR. Review of systemic agents in the treatment of advanced cutaneous squamous cell carcinoma. Future Oncol. 2019;15(27):3171\u201384.","journal-title":"Future Oncol."},{"issue":"2","key":"13306_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","volume":"21","author":"MR Migden","year":"2020","unstructured":"Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21(2):294\u2013305.","journal-title":"Lancet Oncol."},{"issue":"4","key":"13306_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341\u201351.","journal-title":"N Engl J Med."},{"key":"13306_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000775","author":"D Rischin","year":"2020","unstructured":"Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000775.","journal-title":"J Immunother Cancer"},{"key":"13306_CR11","unstructured":"Network NCC. NCCN Clinical practice guidlines in oncology, Squamous cell skin cancer. 2021."},{"key":"13306_CR12","unstructured":"(NVDV) NVvDeV. Plaveiselcelcarcinoom van de huid Richtlijn 2018. 2018."},{"issue":"2","key":"13306_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","volume":"78","author":"SKT Que","year":"2018","unstructured":"Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78(2):237\u201347.","journal-title":"J Am Acad Dermatol."},{"issue":"7","key":"13306_CR14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/hed.20576","volume":"29","author":"MJ Veness","year":"2007","unstructured":"Veness MJ, Porceddu S, Palme CE, Morgan GJ. Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck. 2007;29(7):621\u201331.","journal-title":"Head Neck."},{"issue":"13","key":"13306_CR15","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1245\/s10434-019-07743-8","volume":"26","author":"G Pang","year":"2019","unstructured":"Pang G, Look Hong NJ, Paull G, Dobransky J, Kupper S, Hurton S, et al. Squamous cell carcinoma with regional metastasis to axilla or groin lymph nodes: a multicenter outcome analysis. Ann Surg Oncol. 2019;26(13):4642\u201350.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"13306_CR16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/ans.16584","volume":"91","author":"PF Yang","year":"2021","unstructured":"Yang PF, Veness MJ, Cooper EA, Fox R, Smee RI, Lehane C, et al. Outcomes of patients with metastatic cutaneous squamous cell carcinoma to the axilla: a multicentre cohort study. ANZ J Surg. 2021;91(5):878\u201384.","journal-title":"ANZ J Surg."},{"issue":"7","key":"13306_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/ans.15086","volume":"89","author":"A Sood","year":"2019","unstructured":"Sood A, Wykes J, Roshan D, Wang LY, McGuinness J, Forstner D, et al. Number of nodal metastases and prognosis in metastatic cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg. 2019;89(7):863\u20137.","journal-title":"ANZ J Surg."},{"issue":"4","key":"13306_CR18","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/hed.24683","volume":"39","author":"N Hirshoren","year":"2017","unstructured":"Hirshoren N, Danne J, Dixon BJ, Magarey M, Kleid S, Webb A, et al. Prognostic markers in metastatic cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2017;39(4):772\u20138.","journal-title":"Head Neck."},{"issue":"9","key":"13306_CR19","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","volume":"16","author":"MA Henderson","year":"2015","unstructured":"Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 0.102\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16(9):1049\u201360.","journal-title":"Lancet Oncol."},{"issue":"13","key":"13306_CR20","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2017.77.0941","volume":"36","author":"SV Porceddu","year":"2018","unstructured":"Porceddu SV, Bressel M, Poulsen MG, Stoneley A, Veness MJ, Kenny LM, et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 0501 trial. J Clin Oncol. 2018;36(13):1275\u201383.","journal-title":"J Clin Oncol."},{"issue":"19","key":"13306_CR21","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med."},{"issue":"11","key":"13306_CR22","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655\u201361.","journal-title":"Nat Med."},{"issue":"2","key":"13306_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1200\/JCO.2002.20.2.364","volume":"20","author":"DM Shin","year":"2002","unstructured":"Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002;20(2):364\u201370.","journal-title":"J Clin Oncol."},{"issue":"4","key":"13306_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hed.24662","volume":"39","author":"MK Nottage","year":"2017","unstructured":"Nottage MK, Lin C, Hughes BG, Kenny L, Smith DD, Houston K, et al. Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. Head Neck. 2017;39(4):679\u201383.","journal-title":"Head Neck."},{"issue":"8","key":"13306_CR25","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/1097-0142(19901015)66:8<1692::AID-CNCR2820660807>3.0.CO;2-Y","volume":"66","author":"H Sadek","year":"1990","unstructured":"Sadek H, Azli N, Wendling JL, Cvitkovic E, Rahal M, Mamelle G, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer. 1990;66(8):1692\u20136.","journal-title":"Cancer."},{"key":"13306_CR26","doi-asserted-by":"publisher","first-page":"284582","DOI":"10.1155\/2014\/284582","volume":"2014","author":"RM Samstein","year":"2014","unstructured":"Samstein RM, Ho AL, Lee NY, Barker CA. Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy. J Skin Cancer. 2014;2014:284582.","journal-title":"J Skin Cancer."},{"issue":"25","key":"13306_CR27","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","volume":"29","author":"E Maubec","year":"2011","unstructured":"Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419\u201326.","journal-title":"J Clin Oncol."},{"issue":"2","key":"13306_CR28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/bjd.13741","volume":"173","author":"M Reigneau","year":"2015","unstructured":"Reigneau M, Robert C, Routier E, Mamelle G, Moya-Plana A, Tomasic G, et al. Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. Br J Dermatol. 2015;173(2):527\u201334.","journal-title":"Br J Dermatol."},{"issue":"5","key":"13306_CR29","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/bjd.14936","volume":"176","author":"J Ca\u00f1ueto","year":"2017","unstructured":"Ca\u00f1ueto J, Carde\u00f1oso E, Garc\u00eda JL, Santos-Briz \u00c1, Castellanos-Mart\u00edn A, Fern\u00e1ndez-L\u00f3pez E, et al. Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma. Br J Dermatol. 2017;176(5):1279\u201387.","journal-title":"Br J Dermatol."},{"issue":"17","key":"13306_CR30","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","volume":"387","author":"ND Gross","year":"2022","unstructured":"Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387(17):1557\u201368.","journal-title":"N Engl J Med."},{"issue":"6","key":"13306_CR31","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/bjd.14642","volume":"175","author":"L Borradori","year":"2016","unstructured":"Borradori L, Sutton B, Shayesteh P, Daniels GA. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. Br J Dermatol. 2016;175(6):1382\u20136.","journal-title":"Br J Dermatol."},{"key":"13306_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2017.06.022","volume":"83","author":"T Deinlein","year":"2017","unstructured":"Deinlein T, Lax SF, Schwarz T, Giuffrida R, Schmid-Zalaudek K, Zalaudek I. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature. Eur J Cancer. 2017;83:99\u2013102.","journal-title":"Eur J Cancer."},{"issue":"2","key":"13306_CR33","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/bjd.14664","volume":"176","author":"JK Winkler","year":"2017","unstructured":"Winkler JK, Schneiderbauer R, Bender C, Sedlaczek O, Frohling S, Penzel R, et al. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br J Dermatol. 2017;176(2):498\u2013502.","journal-title":"Br J Dermatol."},{"issue":"11","key":"13306_CR34","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.annonc.2020.07.005","volume":"31","author":"O Michielin","year":"2020","unstructured":"Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1449\u201361.","journal-title":"Ann Oncol."},{"issue":"6","key":"13306_CR35","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178\u201388.","journal-title":"Nat Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13306-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T20:23:05Z","timestamp":1688502185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13306-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["13306"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13306-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"17 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eva A. Huis in \u2019t Veld, Thomas Boere, Charlotte L. Zuur, Michel W. Wouters, Alexander C.J. van Akkooi, John B.A.G. Haanen, Marianne B. Crijns, Myles J. Smith, Antien Mooyaart, Marlies Wakkee, Aniel Sewnaik, Dirk C. Strauss, Dirk J. Grunhagen, Cornelis Verhoef, Andrew J. Hayes, and Winan J. van Houdt have no potential conflicts of interest to declare. Funding This study did not receive any financial or material support.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclousure"}}]}}